These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 29360538)
41. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists. Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587 [TBL] [Abstract][Full Text] [Related]
42. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145 [TBL] [Abstract][Full Text] [Related]
43. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma. Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603 [TBL] [Abstract][Full Text] [Related]
44. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099 [TBL] [Abstract][Full Text] [Related]
45. Differences in DNA methylation patterns and expression of the CCRK gene in human and nonhuman primate cortices. Farcas R; Schneider E; Frauenknecht K; Kondova I; Bontrop R; Bohl J; Navarro B; Metzler M; Zischler H; Zechner U; Daser A; Haaf T Mol Biol Evol; 2009 Jun; 26(6):1379-89. PubMed ID: 19282513 [TBL] [Abstract][Full Text] [Related]
46. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model. Liu H; Shen J; Lu K Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435 [TBL] [Abstract][Full Text] [Related]
47. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein. Wesierska-Gadek J; Schmid G Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931 [TBL] [Abstract][Full Text] [Related]
48. CDK12: an emerging therapeutic target for cancer. Lui GYL; Grandori C; Kemp CJ J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286 [TBL] [Abstract][Full Text] [Related]
49. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302 [TBL] [Abstract][Full Text] [Related]
50. Targeting STAT3 in Cancer Immunotherapy. Zou S; Tong Q; Liu B; Huang W; Tian Y; Fu X Mol Cancer; 2020 Sep; 19(1):145. PubMed ID: 32972405 [TBL] [Abstract][Full Text] [Related]
51. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905 [TBL] [Abstract][Full Text] [Related]
52. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. Liberini V; Laudicella R; Capozza M; Huellner MW; Burger IA; Baldari S; Terreno E; Deandreis D Molecules; 2021 Apr; 26(8):. PubMed ID: 33920423 [TBL] [Abstract][Full Text] [Related]
53. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359 [TBL] [Abstract][Full Text] [Related]
54. CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers. Qi J; Wu G; He M; Xu Y; Yang Z; Ding L; Wang Y; Zhang Z Aging (Albany NY); 2024 Jan; 16(2):1879-1896. PubMed ID: 38261737 [TBL] [Abstract][Full Text] [Related]
55. The Mediator captures CDK7, an attractive transcriptional target in cancer. Wang Y; Manokaran C; Wu S; Roberts TM Cancer Cell; 2021 Sep; 39(9):1184-1186. PubMed ID: 34416166 [TBL] [Abstract][Full Text] [Related]
56. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology]. Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576 [TBL] [Abstract][Full Text] [Related]
57. Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a. Xie C; Song LB; Wu JH; Li J; Yun JP; Lai JM; Xie DY; Lin BL; Yuan YF; Li M; Gao ZL PLoS One; 2012; 7(7):e40607. PubMed ID: 22815774 [TBL] [Abstract][Full Text] [Related]
59. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression. Jin X; Ding D; Yan Y; Li H; Wang B; Ma L; Ye Z; Ma T; Wu Q; Rodrigues DN; Kohli M; Jimenez R; Wang L; Goodrich DW; de Bono J; Dong H; Wu H; Zhu R; Huang H Mol Cell; 2019 Jan; 73(1):22-35.e6. PubMed ID: 30527665 [TBL] [Abstract][Full Text] [Related]
60. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]